Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High rates of vancomycin failure in methicillin-resistant Staphylococcus aureus (MRSA) infections have been increasingly reported over time. The primary objective of our study was to determine the impact of vancomycin exposure and outcomes in patients with MRSA bacteremia initially treated with vancomycin. METHODS: This was a single-center retrospective analysis of 320 patients with documented MRSA bacteremia initially treated with vancomycin from January 2005 through April 2010. Two methods of susceptibility, Etest and broth microdilution, were performed for all isolates to determine the correlation of susceptibility testing to patient outcomes. RESULTS: Among a cohort of 320 patients, more than half (52.5%) experienced vancomycin failure. Independent predictors of vancomycin failure in logistic regression included infective endocarditis (adjusted odds ratio [AOR], 4.55; 95% confidence interval [CI], 2.26-9.15), nosocomial-acquired infection (AOR, 2.19; 95% CI, 1.21-3.97), initial vancomycin trough <15 mg/L (AOR, 2.00; 95% CI, 1.25-3.22), and vancomycin minimum inhibitory concentration (MIC) >1 mg/L by Etest (AOR, 1.52; 95% CI, 1.09-2.49). With use of Classification and Regression Tree (CART) analysis, patients with vancomycin area under the curve at 24 h (AUC(24h)) to MIC ratios <421 were found to have significantly higher rates of failure, compared with patients with AUC(24h) to MIC ratios >421 (61.2% vs 48.6%; P = .038). CONCLUSIONS: In light of the high failure rates associated with this antimicrobial, optimizing the pharmacokinetic/pharmacodynamic properties of vancomycin by targeting higher trough values of 15-20 mg/L and AUC(24h)/MIC ratios ≥400 in selected patients should be considered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Lina, G., Piemont, Y., Godail-Gamot, F., Bes, M., Peter, M.-O., Gauduchon, V., Vandenesch, F., & Etienne, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313461 · Cited by 2,489
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,310
Zhang, K., McClure, J.-A., Elsayed, S., Louie, T., & Conly, J. M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5026-5033.2005 · Cited by 1,037
Cosgrove, S. E., Qi, Y., Kaye, K. S., Harbarth, S., Karchmer, A. W., & Carmeli, Y. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502522 · Cited by 856
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
The emergence and evolution of methicillin-resistant Staphylococcus aureus
Hiramatsu, K., Cui, L., Kuroda, M., & Ito, T. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)02175-8 · Cited by 825
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Self-citationSoriano, A., Marco, F., Martinez, J. A., Pisos, E., Almela, M., Dimova, V. P., Alamo, D., Ortega, M., Lopez, J., & Mensa, J. (2008) · Clinical Infectious Diseases · doi:10.1086/524667 · Cited by 767
Lodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01602-07 · Cited by 574
Lodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L. (2009) · Clinical Infectious Diseases · doi:10.1086/600884 · Cited by 554
Lodise, T. P., Graves, J., Evans, A., Graffunder, E., Helmecke, M., Lomaestro, B. M., & Stellrecht, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-08 · Cited by 553
Klevens, R. M., Edwards, J. R., Tenover, F. C., McDonald, L. C., Horan, T., Gaynes, R., & System, N. N. I. S. (2006) · Clinical Infectious Diseases · doi:10.1086/499367 · Cited by 551
Recursive Partitioning in the Health Sciences
Zhang, H., & Singer, B. (1999) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3027-2 · Cited by 451
Steinkraus, G., White, R., & Friedrich, L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm258 · Cited by 420
Rybak, M. J., Lomaestro, B. M., Rotschafer, J. C., Moellering, R. C., Craig, W. A., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.11.1275 · Cited by 403
Self-citationWang, G., Hindler, J. F., Ward, K. W., & Bruckner, D. A. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01388-06 · Cited by 358
Fowler, Jr., Sakoulas, G., McIntyre, L. M., Meka, V. G., Arbeit, R. D., Cabell, C. H., Stryjewski, M. E., Eliopoulos, G. M., Reller, L. B., Corey, G. R., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/423145 · Cited by 351
Bhavnani, S. M., Rubino, C. M., Ambrose, P. G., & Drusano, G. L. (2010) · Clinical Infectious Diseases · doi:10.1086/652767 · Cited by 280
Jones, R. N. (2006) · Clinical Infectious Diseases · doi:10.1086/491710 · Cited by 254
Howden, B. P., Johnson, P. D. R., Ward, P. B., Stinear, T. P., & Davies, J. K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00422-06 · Cited by 224
Jeffres, M. N., Isakow, W., Doherty, J. A., McKinnon, P. S., Ritchie, D. J., Micek, S. T., & Kollef, M. H. (2006) · Chest · doi:10.1378/chest.130.4.947 · Cited by 219
Lodise, T. P., & McKinnon, P. S. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.02.007 · Cited by 199
Hsu, D. I., Hidayat, L. K., Quist, R., Hindler, J., Karlsson, A., Yusof, A., & Wong-Beringer, A. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.05.007 · Cited by 173
Persistence in Staphylococcus aureus bacteremia: Incidence, characteristics of patients and outcome
Khatib, R., Johnson, L. B., Fakih, M. G., Riederer, K., Khosrovaneh, A., Shamse Tabriz, M., Sharma, M., & Saeed, S. (2006) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540500372846 · Cited by 168
Maor, Y., Hagin, M., Belausov, N., Keller, N., Ben-David, D., & Rahav, G. (2009) · Journal of Infectious Diseases · doi:10.1086/596629 · Cited by 162
Sakoulas, G., Eliopoulos, G. M., Fowler, V. G., Moellering, R. C., Novick, R. P., Lucindo, N., Yeaman, M. R., & Bayer, A. S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2687-2692.2005 · Cited by 162
Khatib, R., Saeed, S., Sharma, M., Riederer, K., Fakih, M. G., & Johnson, L. B. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0096-0 · Cited by 156
Rybak, M. J., Leonard, S. N., Rossi, K. L., Cheung, C. M., Sadar, H. S., & Jones, R. N. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00582-08 · Cited by 156
Self-citationMusta, A. C., RIEDERER, K. M., Shemes, S. P., Chase, P., Jose, J., Johnson, L. B., & Khatib, R. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.02135-08 · Cited by 153
Vancomycin Pharmacokinetics in a Patient Population
Ducharme, M. P., Slaughter, R. L., & Edwards, D. J. (1994) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199410000-00013 · Cited by 146
Editorial: Monitoring Serum Vancomycin Levels: Climbing the Mountain Because It Is There?
Moellering, R. C. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.4.544 · Cited by 123
Wootton, M., MacGowan, A. P., Walsh, T. R., & Howe, R. A. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01508-06 · Cited by 123
Sader, H. S., Fey, P. D., Fish, D. N., Limaye, A. P., Pankey, G. A., Rahal, J. J., Rybak, M. J., Snydman, D. R., Steed, L. L., Waites, K. B., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00616-09 · Cited by 121
Self-citationPharmacodynamics, Pharmacokinetics, and Therapeutic Drug Monitoring of Glycopeptides
MacGowan, A. P. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199810000-00005 · Cited by 108
Tsuji, B. T., Rybak, M. J., Cheung, C. M., Amjad, M., & Kaatz, G. W. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.10.021 · Cited by 105
Self-citationHermsen, E. D., Hanson, M., Sankaranarayanan, J., Stoner, J. A., Florescu, M. C., & Rupp, M. E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903413514 · Cited by 102
(2009) · Emerging Infectious Diseases · doi:10.3201/eid1512.081341 · Cited by 102
Sader, H. S., Rhomberg, P. R., & Jones, R. N. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00093-09 · Cited by 97
Vaudaux, P. E., Huggler, E., Bernard, L., Ferry, T., Renzoni, A., & Lew, D. P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00269-10 · Cited by 53
Rybak, M. J., Leonard, S. N., Rossi, K. L., Cheung, C. M., Sader, H. S., & Jones, R. N. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01981-08 · Cited by 44
Self-citation
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationRybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
Self-citationThe Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance
Kowalska-Krochmal, B., & Dudek-Wicher, R. (2021) · Pathogens · doi:10.3390/pathogens10020165 · Cited by 1,039
Novel antibody-antibiotic conjugate eliminates intracellular S. aureus
Lehar, S. M., Pillow, T., Xu, M., Staben, L., Kajihara, K. K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W. L., Hiroshi Morisaki, J., et al. (2015) · Nature · doi:10.1038/nature16057 · Cited by 838
van Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-12 · Cited by 639
“Despite its adoption, there are (10) limited data to suggest that maintenance of vancomycin trough values between 15 and 20 mg/liter improves outcomes (8, 10).”
BackgroundInfluential
Metadata
- Authors
- Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Wayne State University (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-01
- Volume
- 52
- Issue
- 8
- Pages
- 975-981
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2099365065
- Semantic Scholar
- ed3c7f78a7e345dd4578c14051be67b5da32fd88
- Cited by
- 463
- References
- 44
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 15 · 2023: 15 · 2022: 22 · 2021: 37 · 2020: 33 · 2019: 40 · 2018: 27 · 2017: 26 · 2016: 30 · 2015: 37 · 2014: 43 · 2013: 57 · 2012: 45
- FWCI
- 34.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, methicillin-resistant Staphylococcus aureus, MRSA bacteremia, pharmacokinetic/pharmacodynamic targets, AUC/MIC ratio, trough concentration, infective endocarditis, nosocomial infections, antimicrobial susceptibility testing, E-test, broth microdilution
- MeSH terms
- Anti-Bacterial Agents, Humans, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Staphylococcal Infections, Vancomycin, Bacteremia, Treatment Outcome, Guidelines as Topic, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.